Lilly comments on drug theft at Connecticut facility
INDIANAPOLIS Drugs stolen from an Eli Lilly warehouse in Connecticut Sunday unlikely are to make it into the hands of consumers by legitimate means, the drug maker said Wednesday.
Lilly said it was working with the Food and Drug Administration’s Office of Criminal Investigations to recover drugs stolen from its Enfield, Conn., warehouse. According to published reports, burglars cut a hole in the roof of the warehouse and rappelled inside, stealing around $70 million worth of drugs.
A spokeswoman for Lilly said tight controls in the U.S. pharmaceutical distribution system would make it “extremely difficult” for the stolen drugs to reach patients via legitimate channels, such as retail pharmacies, and products from the affected lots distributed prior to Sunday were not affected. Nevertheless, the company said it was advising doctors, retailers and consumers to check all pharmaceutical products for signs of tampering or damage prior to purchase or use and that it stopped distributing products from the affected lots on Sunday.
Products affected include the psychiatric drugs Prozac (fluoxetine), Cymbalta (duloxetine hydrochloride), Symbyax (olanzapine and fluoxetine hydrochloride) and Zyprexa (olanzapine), the anti-clotting drug Effient (prasugrel) and the injectable cancer drugs Gemzar (gemcitabine hydrochloride) and Alimta (pemetrexed).
PositiveID releases white paper about the health, economic burdens of diabetes
DELRAY BEACH, Fla. PositiveID has published a white paper that describes the health and economic burden of diabetes on Americans and the U.S. economy, the company said Wednesday.
“Fixing the Black Hole in Diabetes Management” discusses how patient care and overall health improves when there is a high quality of patient-clinician collaboration. Additionally, PositiveID noted that diabetics who follow recommended self-monitoring blood-glucose testing-level guidelines may not share the test results with their healthcare providers — the test results are not being used to improve glycemic control and achieve long-term goals, thus getting lost in a “black hole.”
PositiveID pointed out that the use of such monitoring systems as its iGlucose system, which uses wireless SMS messaging to automatically communicate a diabetic’s glucose levels in real-time, can be beneficial to diabetic patients. Citing a a 2009 study, “Excessive Hospitalizations and Its Associated Economic Burden among People with Diabetes in the United States,” found that in 2005, hospital charges alone and medical costs for individuals with diabetes exceeded $171 billion and $90 billion, respectively.
Scott Silverman, PositiveID chairman and CEO said, “We believe the benefits of the iGlucose system are obvious. It can provide improved health outcomes through real-time disease management, simplifying patients’ lives and enhancing vital communication between patients and their healthcare providers. iGlucose also has the ability to decrease fraud and healthcare costs for providers and insurers by automatically creating compliant patient testing logs, which are required to comply with Medicare Part B reimbursement regulations.”
Pending court ruling, Teva to delay marketing Temodar generic
JERUSALEM Teva Pharmaceutical Industries will start marketing its version of a brain tumor drug only if the Federal Circuit of the U.S. District Court upholds a ruling that declared the branded version’s patent unenforceable, Teva announced Wednesday.
The generic drug maker said it had entered an agreement with Schering, now part of Merck & Co., whereby it will market the drug only if the Federal Circuit upholds the U.S. District Court for the District of Delaware’s January ruling that would allow Teva to market a generic version of Schering’s Temodar (temozolomide). The regulatory approval application for the drug was originally filed by Barr Labs, which Teva acquired in 2008.
The agreement also gives Teva to begin selling its version of the drug in August 2013.